Hao Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hao Cheng has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
Yinjing Song
Department of Dermatology Sir Run Run Shaw Hospital School of Medicine Zhejiang University Hangzhou P. R. China
19 shared publicationsChunting Hua
Department of Dermatology and Venereology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
17 shared publicationsSiji Chen
Department of Dermatology and Venereology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China
14 shared publicationsJiang Zhu
Department of Dermatology and Venereology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
12 shared publicationsXia Wu
Department of Dermatology and Venereology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China
11 shared publicationsXianzhen Chen
Department of Dermatology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, China
11 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6593
Real-World Effectiveness, Safety, and 36-Month Persistence of Upadacitinib in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: The 3–6 Month Critical Window and the Role of Early Itch Response and Psychotropic Medication Use
Background/Objectives: Elderly patients (≥65 years) with atopic dermatitis (AD) often carry multimorbidity and face elevated risks with Janus kinase (JAK) inhibitors. Phase III trials included few older adults, and real-world data beyond 12 months remain scarce. We evaluated 36-month efficacy, safety, and drug persistence of upadacitinib 15 mg once daily in 62 Chinese elderly patients. Methods: This retrospective cohort study was conducted at Sir Run Run Shaw Hospital (March 2022-July 2026). All patients received upadacitinib 15 mg once daily. Assessments included Week 4 pruritus Numerical Rating Scale (NRS) response, Eczema Area and Severity Index (EASI) 75/90, and Investigator’s Global Assessment (IGA) 0/1 at Weeks 12 and 24. Drug persistence was estimated with the Kaplan–Meier method (36-month cutoff), and predictors were identified by Cox regression. Results: Median age was 70.0 years, 75.8% were male, and baseline EASI was 34.5, with substantial comorbidity (Charlson Comorbidity Index [CCI] 5.0; psychotropic use 46.8%). Week 4 itch response was 70.8%. EASI 75 reached 75.0% (IGA 0/1 44.4%) at Week 12, rising to 88.0% (64.0%) at Week 24. Persistence declined from 88.7% at Month 3 to 66.1% at Month 6, the steepest drop, reaching 38.7% at Month 36. Treatment-emergent adverse events (TEAEs) occurred in 54.8% and serious adverse events (SAEs) in 8.1%, with herpesvirus infection (21.0%) being the most common event, and there were no adverse event (AE)-related discontinuations, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE). In multivariate analysis, Week 4 itch response predicted longer persistence (hazard ratio [HR] = 0.203, 95% confidence interval [CI]: 0.091-0.452, p < 0.001), while psychotropic medication use predicted shorter persistence (HR = 2.814, 95% CI: 1.237-6.403, p = 0.014). Conclusions: Upadacitinib showed robust efficacy and acceptable safety over 36 months in elderly AD patients. Persistence dropped most sharply between Months 3 and 6. Week 4 itch response and psychotropic medication use independently predicted persistence. A structured Month 3 visit integrating itch reassessment, mental health screening, and dose optimization may improve long-term outcomes.
- 26 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6593
Open AccessReal-World Effectiveness, Safety, and 36-Month Persistence of Upadacitinib in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: The 3–6 Month Critical Window and the Role of Early Itch Response and Psychotropic Medication Use
Background/Objectives: Elderly patients (≥65 years) with atopic dermatitis (AD) often carry multimorbidity and face elevated risks with Janus kinase (JAK) inhibitors. Phase III trials included few older adults, and real-world data beyond 12 months remain scarce. We evaluated 36-month efficacy, safety, and drug persistence of upadacitinib 15 mg once daily in 62 Chinese elderly patients. Methods: This retrospective cohort study was conducted at Sir Run Run Shaw Hospital (March 2022-July 2026). All patients received upadacitinib 15 mg once daily. Assessments included Week 4 pruritus Numerical Rating Scale (NRS) response, Eczema Area and Severity Index (EASI) 75/90, and Investigator’s Global Assessment (IGA) 0/1 at Weeks 12 and 24. Drug persistence was estimated with the Kaplan–Meier method (36-month cutoff), and predictors were identified by Cox regression. Results: Median age was 70.0 years, 75.8% were male, and baseline EASI was 34.5, with substantial comorbidity (Charlson Comorbidity Index [CCI] 5.0; psychotropic use 46.8%). Week 4 itch response was 70.8%. EASI 75 reached 75.0% (IGA 0/1 44.4%) at Week 12, rising to 88.0% (64.0%) at Week 24. Persistence declined from 88.7% at Month 3 to 66.1% at Month 6, the steepest drop, reaching 38.7% at Month 36. Treatment-emergent adverse events (TEAEs) occurred in 54.8% and serious adverse events (SAEs) in 8.1%, with herpesvirus infection (21.0%) being the most common event, and there were no adverse event (AE)-related discontinuations, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE). In multivariate analysis, Week 4 itch response predicted longer persistence (hazard ratio [HR] = 0.203, 95% confidence interval [CI]: 0.091-0.452, p < 0.001), while psychotropic medication use predicted shorter persistence (HR = 2.814, 95% CI: 1.237-6.403, p = 0.014). Conclusions: Upadacitinib showed robust efficacy and acceptable safety over 36 months in elderly AD patients. Persistence dropped most sharply between Months 3 and 6. Week 4 itch response and psychotropic medication use independently predicted persistence. A structured Month 3 visit integrating itch reassessment, mental health screening, and dose optimization may improve long-term outcomes.
- 22 July 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 187, 117164
Pectolinarigenin alleviates psoriasis via inhibition of keratinocyte hyperproliferation and inflammatory signaling
- 22 July 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 187, 117164
Pectolinarigenin alleviates psoriasis via inhibition of keratinocyte hyperproliferation and inflammatory signaling
- Open Access
- 20 July 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (48) , e74198
A Metamaterial Buckling‐Assisted Surface‐Acoustic‐Wave Enabled Sensor (mBASES) for Versatile and Ultrasensitive Biomarker Detection
Hydrogel metamaterials with programmable microarchitectures offer a promising route for converting molecular recognition into mechanical responses. However, efficiently transducing weak biomolecular perturbations into detectable signals without relying on molecular amplification remains a fundamental challenge. Here, we report a metamaterial Buckling‐Assisted Surface‐acoustic‐wave Enabled Sensor (mBASES), which introduces a structure‐triggered physical amplification mechanism by integrating bio‐crosslinked hydrogel metamaterials with a surface acoustic wave (SAW) device. Through competitive biomolecular recognition, target binding induces hydrogel swelling that is engineered to match the critical buckling threshold of the metamaterial. This instability‐enabled pattern transformation acts as an intrinsic mechanical gain element, converting weak molecular perturbations into amplified acoustic responses through coupled modulation of phononic transmission and hydrogel–SAW interactions. As a result, mBASES establishes a transduction pathway that links molecular recognition, hydrogel deformation, structural amplification, and ultimately acoustic readout. The platform enables rapid, label‐free detection across multiple biomolecular classes, including proteins, nucleic acids, and metabolites. Clinical validation further demonstrates femtomolar‐level detection of Herpes Simplex Virus (HSV) IgG and unamplified DNA in human serum within 5–15 min using a one‐step assay. By amplifying the transduction process rather than the target molecules, mBASES establishes a versatile biosensing strategy, providing a promising platform for point‐of‐care diagnostics.
- 20 July 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (48) , e74198
Open AccessA Metamaterial Buckling‐Assisted Surface‐Acoustic‐Wave Enabled Sensor (mBASES) for Versatile and Ultrasensitive Biomarker Detection
Hydrogel metamaterials with programmable microarchitectures offer a promising route for converting molecular recognition into mechanical responses. However, efficiently transducing weak biomolecular perturbations into detectable signals without relying on molecular amplification remains a fundamental challenge. Here, we report a metamaterial Buckling‐Assisted Surface‐acoustic‐wave Enabled Sensor (mBASES), which introduces a structure‐triggered physical amplification mechanism by integrating bio‐crosslinked hydrogel metamaterials with a surface acoustic wave (SAW) device. Through competitive biomolecular recognition, target binding induces hydrogel swelling that is engineered to match the critical buckling threshold of the metamaterial. This instability‐enabled pattern transformation acts as an intrinsic mechanical gain element, converting weak molecular perturbations into amplified acoustic responses through coupled modulation of phononic transmission and hydrogel–SAW interactions. As a result, mBASES establishes a transduction pathway that links molecular recognition, hydrogel deformation, structural amplification, and ultimately acoustic readout. The platform enables rapid, label‐free detection across multiple biomolecular classes, including proteins, nucleic acids, and metabolites. Clinical validation further demonstrates femtomolar‐level detection of Herpes Simplex Virus (HSV) IgG and unamplified DNA in human serum within 5–15 min using a one‐step assay. By amplifying the transduction process rather than the target molecules, mBASES establishes a versatile biosensing strategy, providing a promising platform for point‐of‐care diagnostics.
- Open Access
- 8 July 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (3) , 1-14
Phenylalanine exacerbates psoriasiform inflammation through NF‑κB‑mediated dendritic cell activation and Th17 polarization
Metabolic dysregulation has been increasingly recognized as a key driver in the pathogenesis of psoriasis; however, the specific mechanistic contributions of amino acid perturbations remain poorly understood. The present study, through comprehensive metabolomic profiling, observed a marked accumulation of phenylalanine in both the circulation and skin lesions of psoriatic mice. Notably, a high‑phenylalanine diet exacerbated psoriasiform skin inflammation of imiquimod‑induced psoriasis, whereas dietary restriction of phenylalanine or administration of L‑type amino acid transporter inhibitors effectively alleviated skin inflammation. Mechanistically, transcriptome sequencing of dendritic cells identified phenylalanine as a potent metabolic trigger. The present analysis revealed that high phenylalanine levels alone significantly elevated the baseline expression of notable pro‑inflammatory cytokines and this inflammatory response was further amplified in the presence of imiquimod. The present study determined that this pro‑inflammatory effect was mediated through the NF‑κB signaling pathway, which subsequently promoted the differentiation of T helper 17 cells. Collectively, the present findings uncovered a previously unrecognized metabolic checkpoint in psoriasis and suggested that restriction of phenylalanine represents a promising, non‑toxic adjunctive therapeutic strategy for the clinical management of psoriasis.
- 8 July 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (3) , 1-14
Open AccessPhenylalanine exacerbates psoriasiform inflammation through NF‑κB‑mediated dendritic cell activation and Th17 polarization
Metabolic dysregulation has been increasingly recognized as a key driver in the pathogenesis of psoriasis; however, the specific mechanistic contributions of amino acid perturbations remain poorly understood. The present study, through comprehensive metabolomic profiling, observed a marked accumulation of phenylalanine in both the circulation and skin lesions of psoriatic mice. Notably, a high‑phenylalanine diet exacerbated psoriasiform skin inflammation of imiquimod‑induced psoriasis, whereas dietary restriction of phenylalanine or administration of L‑type amino acid transporter inhibitors effectively alleviated skin inflammation. Mechanistically, transcriptome sequencing of dendritic cells identified phenylalanine as a potent metabolic trigger. The present analysis revealed that high phenylalanine levels alone significantly elevated the baseline expression of notable pro‑inflammatory cytokines and this inflammatory response was further amplified in the presence of imiquimod. The present study determined that this pro‑inflammatory effect was mediated through the NF‑κB signaling pathway, which subsequently promoted the differentiation of T helper 17 cells. Collectively, the present findings uncovered a previously unrecognized metabolic checkpoint in psoriasis and suggested that restriction of phenylalanine represents a promising, non‑toxic adjunctive therapeutic strategy for the clinical management of psoriasis.
- 16 February 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1067-1076
Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial
Background: Moderate-to-severe atopic dermatitis (AD) imposes a significant burden on adolescents and their families, leading to a substantial reduction in quality of life. Treatment options remain limited. Stapokibart, a novel humanized monoclonal antibody that targets interleukin-4Rα, has been approved in China for the treatment of adults with moderate-to-severe AD. Objectives: To evaluate the efficacy and safety of stapokibart in adolescents with moderate-to-severe AD. Methods: In this randomized double-blind placebo-controlled phase III trial (NCT06277765), eligible patients were randomized (2 : 1) to stapokibart 300 mg (loading dose 600 mg) or placebo for 18 weeks. Patients with a baseline weight ≥ 60 kg received subcutaneous stapokibart or placebo every 2 weeks (Q2W), while those weighing 30 to < 60 kg received treatment every 3 weeks (Q3W). All patients were given moisturizers during the entire study period. Co-primary endpoints were the proportions of patients achieving a ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI 75) and an Investigator’s Global Assessment (IGA) score of clear or almost clear (IGA 0 or 1) with ≥ 2-point reduction from baseline (IGA response) at week 18. Safety was also assessed. Results: Of the 180 enrolled patients, 120 received stapokibart (Q2W, n = 54; Q3W, n = 66) and 60 received placebo (Q2W, n = 26; Q3W, n = 34). In total, 178 (98.9%) patients completed the double-blind treatment. At week 18, higher proportions of patients treated with stapokibart than those treated with placebo achieved EASI 75 [73.9% (n = 88/119) vs. 43% (n = 26/60); difference: 30.5% (95% confidence interval 15.3–44.3; P < 0.001)] and an IGA response [57.1% (n = 68/119) vs. 25% (n = 15/60); difference: 31.8% (95% confidence interval 16.6–44.4; P < 0.001)]. The proportion of patients achieving ≥ 4-point reductions in weekly average of daily Peak Pruritus Numerical Rating Scale score was also significantly higher in the stapokibart group than in the placebo group [36.1% (n = 43/119) vs. 15% (n = 9/60); difference: 21.1% (95% confidence interval 7.4–32.4; P = 0.004)]. The incidence of adverse events was similar between the stapokibart (62.5%; n = 75/120) and placebo (62%; n = 37/60) groups. No conjunctivitis was seen. Conclusions: Stapokibart has a high efficacy and favourable safety in adolescents with moderate-to-severe AD. An author video to accompany this article is available online.
- 16 February 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1067-1076
Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial
Background: Moderate-to-severe atopic dermatitis (AD) imposes a significant burden on adolescents and their families, leading to a substantial reduction in quality of life. Treatment options remain limited. Stapokibart, a novel humanized monoclonal antibody that targets interleukin-4Rα, has been approved in China for the treatment of adults with moderate-to-severe AD. Objectives: To evaluate the efficacy and safety of stapokibart in adolescents with moderate-to-severe AD. Methods: In this randomized double-blind placebo-controlled phase III trial (NCT06277765), eligible patients were randomized (2 : 1) to stapokibart 300 mg (loading dose 600 mg) or placebo for 18 weeks. Patients with a baseline weight ≥ 60 kg received subcutaneous stapokibart or placebo every 2 weeks (Q2W), while those weighing 30 to < 60 kg received treatment every 3 weeks (Q3W). All patients were given moisturizers during the entire study period. Co-primary endpoints were the proportions of patients achieving a ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI 75) and an Investigator’s Global Assessment (IGA) score of clear or almost clear (IGA 0 or 1) with ≥ 2-point reduction from baseline (IGA response) at week 18. Safety was also assessed. Results: Of the 180 enrolled patients, 120 received stapokibart (Q2W, n = 54; Q3W, n = 66) and 60 received placebo (Q2W, n = 26; Q3W, n = 34). In total, 178 (98.9%) patients completed the double-blind treatment. At week 18, higher proportions of patients treated with stapokibart than those treated with placebo achieved EASI 75 [73.9% (n = 88/119) vs. 43% (n = 26/60); difference: 30.5% (95% confidence interval 15.3–44.3; P < 0.001)] and an IGA response [57.1% (n = 68/119) vs. 25% (n = 15/60); difference: 31.8% (95% confidence interval 16.6–44.4; P < 0.001)]. The proportion of patients achieving ≥ 4-point reductions in weekly average of daily Peak Pruritus Numerical Rating Scale score was also significantly higher in the stapokibart group than in the placebo group [36.1% (n = 43/119) vs. 15% (n = 9/60); difference: 21.1% (95% confidence interval 7.4–32.4; P = 0.004)]. The incidence of adverse events was similar between the stapokibart (62.5%; n = 75/120) and placebo (62%; n = 37/60) groups. No conjunctivitis was seen. Conclusions: Stapokibart has a high efficacy and favourable safety in adolescents with moderate-to-severe AD. An author video to accompany this article is available online.
- Open Access
- 4 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Integrative metabolomic and single-cell transcriptomic analysis of recurrent condyloma acuminatum in humans
Condyloma acuminatum (CA), primarily caused by low-risk HPV6/11, is a benign proliferative disease that is difficult to cure and prone to recurrence. However, the molecular and immune mechanisms underlying relapse remain unclear. We combined metabolomic profiling with single-cell RNA sequencing to investigate recurrence-associated changes. Metabolomics revealed dysregulation of ascorbate and aldarate, glycerophospholipid, purine, and arginine/proline metabolism in recurrent CA. Single-cell analysis identified altered expression of metabolism-related genes (AMD1, GSTM3, ALDH3A1, GPX1, GPX4) in keratinocytes, associated with hyperproliferation, impaired differentiation, and ferroptosis resistance. Immune profiling identified transcriptionally distinct myeloid subpopulations in recurrent CA lesions, including M2 macrophages and dendritic cells. KEGG analysis indicated enrichment of antigen processing, phagosome, and endocytosis pathways in M2 macrophages, and antigen processing and viral carcinogenesis in dendritic cells, suggesting altered immune regulatory states. Notably, the key polyamine biosynthesis regulator AMD1 was downregulated in both M2 macrophages and dendritic cells in recurrent lesions, paralleling metabolic evidence of altered arginine-polyamine pathways. These findings suggest that recurrent CA involves coordinated metabolic dysregulation across keratinocytes and immune cells, highlighting potential targets for immunometabolic intervention.
- 4 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessIntegrative metabolomic and single-cell transcriptomic analysis of recurrent condyloma acuminatum in humans
Condyloma acuminatum (CA), primarily caused by low-risk HPV6/11, is a benign proliferative disease that is difficult to cure and prone to recurrence. However, the molecular and immune mechanisms underlying relapse remain unclear. We combined metabolomic profiling with single-cell RNA sequencing to investigate recurrence-associated changes. Metabolomics revealed dysregulation of ascorbate and aldarate, glycerophospholipid, purine, and arginine/proline metabolism in recurrent CA. Single-cell analysis identified altered expression of metabolism-related genes (AMD1, GSTM3, ALDH3A1, GPX1, GPX4) in keratinocytes, associated with hyperproliferation, impaired differentiation, and ferroptosis resistance. Immune profiling identified transcriptionally distinct myeloid subpopulations in recurrent CA lesions, including M2 macrophages and dendritic cells. KEGG analysis indicated enrichment of antigen processing, phagosome, and endocytosis pathways in M2 macrophages, and antigen processing and viral carcinogenesis in dendritic cells, suggesting altered immune regulatory states. Notably, the key polyamine biosynthesis regulator AMD1 was downregulated in both M2 macrophages and dendritic cells in recurrent lesions, paralleling metabolic evidence of altered arginine-polyamine pathways. These findings suggest that recurrent CA involves coordinated metabolic dysregulation across keratinocytes and immune cells, highlighting potential targets for immunometabolic intervention.
- Open Access
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 12, 1720876
Glutamate enhances the production of inflammatory cytokines IL-6 and IL-11, as well as chemokines CXCL2, CXCL3, and CXCL8 in keloid fibroblasts
Introduction: Keloids are fibroproliferative skin scars characterized by excessive extracellular matrix deposition and a high rate of recurrence. Despite extensive research, their pathogenesis remains incompletely understood and effective curative therapies are lacking. Methods: RNA sequencing (RNA-seq) and metabolomics were performed to compare gene expression and metabolite profiles between human keloid tissues and normal skin. Single-cell RNA sequencing, immunohistochemistry, and immunofluorescence were used to determine the cellular localization of key genes. In vitro , human fibroblasts were stimulated with glutamate, followed by RNA-seq, quantitative RT-PCR, and ELISA to evaluate inflammatory gene expression and cytokine secretion. Results: Transcriptomic analysis revealed significant enrichment of the neuroactive ligand-receptor interaction pathway in keloid tissue, with marked upregulation of the glutamate receptor subunit GRIN2D. Single-cell and histological analyses demonstrated that GRIN2D is predominantly expressed in fibroblasts. Metabolomic profiling showed significantly increased levels of glutamate and glutamine in keloid tissues. Glutamate stimulation of fibroblasts significantly enhanced the expression and secretion of inflammatory cytokines IL-6 and IL-11, as well as chemokines CXCL2, CXCL3, and CXCL8 (IL-8). Discussion: These results underscore the crucial role of glutamate metabolism in promoting the infammatory functions of fbroblasts. They suggest that glutamate contributes to keloid progression and provides a theoretical basis for targeting glutamte signaling pathway in keloid treatment.
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 12, 1720876
Open AccessGlutamate enhances the production of inflammatory cytokines IL-6 and IL-11, as well as chemokines CXCL2, CXCL3, and CXCL8 in keloid fibroblasts
Introduction: Keloids are fibroproliferative skin scars characterized by excessive extracellular matrix deposition and a high rate of recurrence. Despite extensive research, their pathogenesis remains incompletely understood and effective curative therapies are lacking. Methods: RNA sequencing (RNA-seq) and metabolomics were performed to compare gene expression and metabolite profiles between human keloid tissues and normal skin. Single-cell RNA sequencing, immunohistochemistry, and immunofluorescence were used to determine the cellular localization of key genes. In vitro , human fibroblasts were stimulated with glutamate, followed by RNA-seq, quantitative RT-PCR, and ELISA to evaluate inflammatory gene expression and cytokine secretion. Results: Transcriptomic analysis revealed significant enrichment of the neuroactive ligand-receptor interaction pathway in keloid tissue, with marked upregulation of the glutamate receptor subunit GRIN2D. Single-cell and histological analyses demonstrated that GRIN2D is predominantly expressed in fibroblasts. Metabolomic profiling showed significantly increased levels of glutamate and glutamine in keloid tissues. Glutamate stimulation of fibroblasts significantly enhanced the expression and secretion of inflammatory cytokines IL-6 and IL-11, as well as chemokines CXCL2, CXCL3, and CXCL8 (IL-8). Discussion: These results underscore the crucial role of glutamate metabolism in promoting the infammatory functions of fbroblasts. They suggest that glutamate contributes to keloid progression and provides a theoretical basis for targeting glutamte signaling pathway in keloid treatment.
- 29 November 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (4) , 629-639
Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial
Background: Effective topical therapies for mild-to-moderate atopic dermatitis (AD) should provide rapid itch relief, sustained anti-inflammatory efficacy and minimal local toxicity. Existing options, including corticosteroids and calcineurin inhibitors, are limited by long-term adverse effects, highlighting the need for safer, steroid-sparing alternatives. Objectives: To evaluate the efficacy and safety of ivarmacitinib ointment, a highly selective topical Janus kinase 1 inhibitor, applied twice daily in adults with mild-to-moderate AD. Methods: This phase III evaluation was part of a multicentre randomized double-blind vehicle-controlled seamless adaptive phase II/III trial conducted at 27 sites in China. Adults aged 18–75 years with Hanifin–Rajka-defined mild-to-moderate AD were randomized (1 : 1 : 1) to ivarmacitinib ointment 0.5%, ivarmacitinib ointment 1% or vehicle for 8 weeks. Patients who initially received the vehicle were re-randomized to active treatment for a blinded extension through week 52. Co-primary endpoints were Investigator’s Global Assessment (IGA) response (score 0/1 with ≥ 2-grade improvement) and ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 8. Results: At week 8, significantly more patients achieved an IGA response with ivarmacitinib than with vehicle [ivarmacitinib 0.5%: 21.3% vs. 10.6% (P = 0.02); ivarmacitinib 1%: 26.2% vs. 10.6% (P = 0.001)]. Likewise, EASI 75 responses were higher [ivarmacitinib 0.5%: 42.6% vs. 17.9%; ivarmacitinib 1%: 45.1% vs. 17.9% (both P < 0.001)]. Relief from pruritus was seen within 48 h and maintained through week 52, with sustained improvements in SCORing Atopic Dermatitis (SCORAD), affected body surface area and Dermatology Life Quality Index. During the vehicle-controlled period, treatment-emergent adverse events occurred in 42.6% (n = 52/122), 56.6% (n = 69/122) and 52.0% (n = 64/123) of patients in the ivarmacitinib 0.5%, ivarmacitinib 1% and vehicle groups, respectively; most were mild and infection-related events were infrequent. No treatment-related adverse event occurred in ≥ 2% of patients in the ivarmacitinib 1% or vehicle groups, while in the ivarmacitinib 0.5% group, only folliculitis (n = 5/122; 4.1%) and increased blood uric acid (n = 4/122; 3.3%) were reported in ≥ 2% of patients. No skin atrophy, telangiectasia or application-site irritation was observed. Long-term safety through week 52 remained consistent, with no new safety signals noted. Conclusions: Twice-daily ivarmacitinib ointment (0.5% or 1%) produced rapid, durable and well-tolerated improvements in the signs, symptoms and itch experienced by adults with mild-to-moderate AD, supporting its potential as a safe, steroid-sparing topical therapy.
- 29 November 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (4) , 629-639
Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial
Background: Effective topical therapies for mild-to-moderate atopic dermatitis (AD) should provide rapid itch relief, sustained anti-inflammatory efficacy and minimal local toxicity. Existing options, including corticosteroids and calcineurin inhibitors, are limited by long-term adverse effects, highlighting the need for safer, steroid-sparing alternatives. Objectives: To evaluate the efficacy and safety of ivarmacitinib ointment, a highly selective topical Janus kinase 1 inhibitor, applied twice daily in adults with mild-to-moderate AD. Methods: This phase III evaluation was part of a multicentre randomized double-blind vehicle-controlled seamless adaptive phase II/III trial conducted at 27 sites in China. Adults aged 18–75 years with Hanifin–Rajka-defined mild-to-moderate AD were randomized (1 : 1 : 1) to ivarmacitinib ointment 0.5%, ivarmacitinib ointment 1% or vehicle for 8 weeks. Patients who initially received the vehicle were re-randomized to active treatment for a blinded extension through week 52. Co-primary endpoints were Investigator’s Global Assessment (IGA) response (score 0/1 with ≥ 2-grade improvement) and ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 8. Results: At week 8, significantly more patients achieved an IGA response with ivarmacitinib than with vehicle [ivarmacitinib 0.5%: 21.3% vs. 10.6% (P = 0.02); ivarmacitinib 1%: 26.2% vs. 10.6% (P = 0.001)]. Likewise, EASI 75 responses were higher [ivarmacitinib 0.5%: 42.6% vs. 17.9%; ivarmacitinib 1%: 45.1% vs. 17.9% (both P < 0.001)]. Relief from pruritus was seen within 48 h and maintained through week 52, with sustained improvements in SCORing Atopic Dermatitis (SCORAD), affected body surface area and Dermatology Life Quality Index. During the vehicle-controlled period, treatment-emergent adverse events occurred in 42.6% (n = 52/122), 56.6% (n = 69/122) and 52.0% (n = 64/123) of patients in the ivarmacitinib 0.5%, ivarmacitinib 1% and vehicle groups, respectively; most were mild and infection-related events were infrequent. No treatment-related adverse event occurred in ≥ 2% of patients in the ivarmacitinib 1% or vehicle groups, while in the ivarmacitinib 0.5% group, only folliculitis (n = 5/122; 4.1%) and increased blood uric acid (n = 4/122; 3.3%) were reported in ≥ 2% of patients. No skin atrophy, telangiectasia or application-site irritation was observed. Long-term safety through week 52 remained consistent, with no new safety signals noted. Conclusions: Twice-daily ivarmacitinib ointment (0.5% or 1%) produced rapid, durable and well-tolerated improvements in the signs, symptoms and itch experienced by adults with mild-to-moderate AD, supporting its potential as a safe, steroid-sparing topical therapy.
- Open Access
- 14 November 2025
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2583577
Effect of human papillomavirus (HPV) vaccine on HPV type replacement and sexual behaviors in the post-vaccine era: A cross-sectional study
Human Papillomavirus (HPV) vaccination has been implemented for more than 15 years to prevent HPV infection and associated precancerous lesions. However, limited data are available regarding the long-term impacts of HPV vaccination, particularly concerning cross-protection and type replacement. Using data from the 2007-2016 National Health and Nutrition Examination Survey (NHANES), we employed the survey-weighted Student's t-tests, chi-square tests, and logistic regression models to examine the association between vaccine effectiveness and timing of vaccination. Among 9040 females aged 18 years and over, vaccination showed great effectiveness against both vaccine-targeted and non-vaccine-targeted high-risk HPV (hrHPV) among those vaccinated before sexual debut. After full adjustment, participants vaccinated after sex had a 48% increased risk of hrHPV infection (OR (95% CI) = 1.48 (1.16, 1.88)) compared to unvaccinated participants, and their sexual behaviors were more active as well. The most prevalent HPV subtypes were HPV 16/51/52/66, and the prevalence of subtypes 18/35/52/66/68 differed significantly across racial groups. Despite the prevalence of most hrHPV subtypes declined continuously or fluctuated over time, it is noteworthy that the infection rate of HPV 66 increased by 59% compared to the unvaccinated (95% CI: 0.18-0.92). Continuous surveillance is warranted for hrHPV types antigenically distant from vaccine strains, as early type replacement may be emerging. Given the notable difference in effectiveness based on vaccination timing, public-health education should emphasize both the benefits and limitations of HPV vaccination in the context of sexual health.
- 14 November 2025
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2583577
Open AccessEffect of human papillomavirus (HPV) vaccine on HPV type replacement and sexual behaviors in the post-vaccine era: A cross-sectional study
Human Papillomavirus (HPV) vaccination has been implemented for more than 15 years to prevent HPV infection and associated precancerous lesions. However, limited data are available regarding the long-term impacts of HPV vaccination, particularly concerning cross-protection and type replacement. Using data from the 2007-2016 National Health and Nutrition Examination Survey (NHANES), we employed the survey-weighted Student's t-tests, chi-square tests, and logistic regression models to examine the association between vaccine effectiveness and timing of vaccination. Among 9040 females aged 18 years and over, vaccination showed great effectiveness against both vaccine-targeted and non-vaccine-targeted high-risk HPV (hrHPV) among those vaccinated before sexual debut. After full adjustment, participants vaccinated after sex had a 48% increased risk of hrHPV infection (OR (95% CI) = 1.48 (1.16, 1.88)) compared to unvaccinated participants, and their sexual behaviors were more active as well. The most prevalent HPV subtypes were HPV 16/51/52/66, and the prevalence of subtypes 18/35/52/66/68 differed significantly across racial groups. Despite the prevalence of most hrHPV subtypes declined continuously or fluctuated over time, it is noteworthy that the infection rate of HPV 66 increased by 59% compared to the unvaccinated (95% CI: 0.18-0.92). Continuous surveillance is warranted for hrHPV types antigenically distant from vaccine strains, as early type replacement may be emerging. Given the notable difference in effectiveness based on vaccination timing, public-health education should emphasize both the benefits and limitations of HPV vaccination in the context of sexual health.
- Open Access
- 14 November 2025
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 57 (1) , 1-18
Human papillomavirus E7 inhibits immune responses in keratinocytes by activating HTRA1‑mediated mitophagy
Persistent infection with human papillomavirus (HPV) can lead to refractory disease. The HPV E7 protein causes persistent viral infection by disrupting the immune balance of keratinocytes; however, its key mechanism is not yet clear. Overexpression of the HPV E7 gene in normal human epidermal keratinocytes can promote mitophagy in the host cells and inhibit the expression of type I interferon (IFN), as previously confirmed by electron microscopy, immunofluorescence and western blot analysis. In the present study, Siha cells with stable knockdown of HPV16 E7 were constructed, and RNA sequencing at the transcription level and isobaric tags for relative and absolute quantitation analysis at the protein level were performed, with the aim of identifying genes related to mitophagy among the differentially expressed genes. Using immunohistochemistry, PCR and western blotting, significant differences were detected in the expression levels of high‑temperature requirement A serine peptidase 1 (HTRA1) between the knockdown and control groups. The results confirmed that HPV E7 could promote the expression of HTRA1. Furthermore, it was demonstrated that the HPV E7 protein interacted with HTRA1 intracellularly to activate the PTEN‑induced kinase 1 (PINK1)/Parkin pathway in keratinocytes, leading to enhanced mitophagy and reduced expression of type I IFN in host cells. In conclusion, HPV E7 could promote the expression of the HTRA1 gene in keratinocytes, thereby activating mitophagy mediated by the PINK1/Parkin pathway. Furthermore, HPV E7 could inhibit the secretion of type I IFN from cells, thus leading to persistent viral infection. These findings provide novel insights into the association between HPV infection and mitophagy, and may elucidate the mechanisms underlying persistent HPV infection.1
- 14 November 2025
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 57 (1) , 1-18
Open AccessHuman papillomavirus E7 inhibits immune responses in keratinocytes by activating HTRA1‑mediated mitophagy
Persistent infection with human papillomavirus (HPV) can lead to refractory disease. The HPV E7 protein causes persistent viral infection by disrupting the immune balance of keratinocytes; however, its key mechanism is not yet clear. Overexpression of the HPV E7 gene in normal human epidermal keratinocytes can promote mitophagy in the host cells and inhibit the expression of type I interferon (IFN), as previously confirmed by electron microscopy, immunofluorescence and western blot analysis. In the present study, Siha cells with stable knockdown of HPV16 E7 were constructed, and RNA sequencing at the transcription level and isobaric tags for relative and absolute quantitation analysis at the protein level were performed, with the aim of identifying genes related to mitophagy among the differentially expressed genes. Using immunohistochemistry, PCR and western blotting, significant differences were detected in the expression levels of high‑temperature requirement A serine peptidase 1 (HTRA1) between the knockdown and control groups. The results confirmed that HPV E7 could promote the expression of HTRA1. Furthermore, it was demonstrated that the HPV E7 protein interacted with HTRA1 intracellularly to activate the PTEN‑induced kinase 1 (PINK1)/Parkin pathway in keratinocytes, leading to enhanced mitophagy and reduced expression of type I IFN in host cells. In conclusion, HPV E7 could promote the expression of the HTRA1 gene in keratinocytes, thereby activating mitophagy mediated by the PINK1/Parkin pathway. Furthermore, HPV E7 could inhibit the secretion of type I IFN from cells, thus leading to persistent viral infection. These findings provide novel insights into the association between HPV infection and mitophagy, and may elucidate the mechanisms underlying persistent HPV infection.1